ArticleObesity facts2021
Canagliflozin: A New Therapeutic Option in Patients That Present Postprandial Hyperinsulinemic Hypoglycemia after Roux-en-Y Gastric Bypass: A Pilot Study.
Article in Obesity facts, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Dumping Syndrome After One Anastomosis Gastric Bypass-A Systematic Review.Obesity surgery · 2025Pooled it
- European guideline on obesity care in patients with gastrointestinal and liver diseases - Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline.United European gastroenterology journal · 2022Guideline
- Acarbose or Canagliflozin vs. Placebo to Ameliorate Post-Bariatric Hypoglycaemia: The Clinical Outcomes of the HypoBar I Randomised Clinical Trial.Diabetes, obesity & metabolism · 2026Trial
- Post-bariatric hypoglycaemia: from altered gut physiology to targeted therapies.Endocrine connections · 2026Article
- Managing post-bariatric hypoglycemia: a systematic review of pharmacological therapies.Diabetology & metabolic syndrome · 2025Article
- Nesidioblastosis in Patients With Severe Postbariatric Hypoglycemia: A Monocentric Case Series.Journal of the Endocrine Society · 2025Article
- Endoscopic argon plasma coagulation treatment for late dumping syndrome in patients with Roux-en-Y gastric bypass.Frontiers in endocrinology · 2025Article
- Remission of type 2 diabetes: position statement of the Italian society of diabetes (SID).Acta diabetologica · 2024Article
- Society for Endocrinology guidelines for the diagnosis and management of post-bariatric hypoglycaemia.Endocrine connections · 2024Review
- Postprandial hypoglycemia as a complication of bariatric and metabolic surgery: a comprehensive review of literature.Frontiers in surgery · 2024Review
- [Postoperative management].Wiener klinische Wochenschrift · 2023Article
- Dumping Syndrome in Children: A Narrative Review.Cureus · 2023Review
- Hypoglycemia post bariatric surgery: drugs with different mechanisms of action to treat a unique disorder.Archives of endocrinology and metabolism · 2023Review
- Case Report: Post-gastrectomy reactive hyperinsulinemic hypoglicaemia: glucose trends before and after canagliflozin treatment.Frontiers in endocrinology · 2023Article
- Dumping Syndrome: Pragmatic Treatment Options and Experimental Approaches for Improving Clinical Outcomes.Clinical and experimental gastroenterology · 2023Review
- Outpatient Treatment of Postbariatric Hypoglycemia With Canagliflozin.AACE endocrinology and diabetesArticle
- Diagnosis and Management of Post-Bariatric Hypoglycemia.Journal of the American Board of Family Medicine : JABFMReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRoux-en-Y gastric bypass (RYGB) is the most common surgical procedure for morbid obesity. However, it can present serious late complications, like postprandial hyperinsulinemic hypoglycemia (PHH). Recent data suggested an increase in intestinal SGLT-1 after RYGB. However, there is no data on the inhibition of SGLT-1 to prevent PHH in patients with prior RYBG. On this basis, we aimed to evaluate (a) the effect of canagliflozin 300 mg on the response to 100 g glucose overload (oral glucose tolerance test [OGTT]); (b) the pancreatic response after intra-arterial calcium stimulation in the context of PHH after RYGB. MATERIALS AND
methodsThis is a prospective pilot study including patients (n = 21) with PHH after RYGB, matched by age and gender with healthy controls (n = 5). Basal OGTT and after 2 weeks of daily 300 mg of canagliflozin was performed in all cases. In addition, venous sampling after intra-arterial calcium stimulation of the pancreas was performed in 10 cases.
resultsOGTT after canagliflozin showed a significant reduction of plasma glucose levels (minute 30: 161.5 ± 36.22 vs. 215.9 ± 58.11 mg/dL; minute 60: 187.46 ± 65.88 vs. 225.9 ± 85.60 mg/dL, p < 0.01) and insulinemia (minute 30: 95.6 ± 27.31 vs. 216.35 ± 94.86 mg/dL, p = 0.03; minute 60: 120.85 ± 94.86 vs. 342.64 ± 113.32 mIU/L, p < 0.001). At minute 180, a significant reduction (85.7%) of the rate of hypoglycemia was observed after treatment with canagliflozin (p < 0.00001). All cases presented normal pancreatic response after intra-arterial calcium administration.
conclusionCanagliflozin (300 mg) significantly decreased glucose absorption and prevented PHH after 100 g OGTT in patients with RYGB. Our results suggest that canagliflozin could be a new therapeutic option for patients that present PHH after RYGB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.